With the inauguration of Donald Trump as president on January 20th, the editors asked some of our Xconomists to offer their thoughts on “How could the incoming administration significantly affect your industry?” When I worked in the Reagan Administration, the “Gipper” used to handle questions like this by saying he couldn’t respond to hypothetical questions. … Continue reading “Watching for NIH Innovation in 2017—and Drug Pricing, Trade Deals”
Author: Joe Panetta
Joseph Panetta is President and CEO and a member of the Board of Directors of Biocom, the Southern California association that advocates for more than 550 companies, service sector firms, universities and research institutes working in the life sciences. As the head of Biocom since 1999, Panetta has lead programs in capital formation, public policy, workforce education, and member services. He oversees several subsidiaries of Biocom, including a purchasing group that provides more than $35 million in products and services to members. He co-founded the Biocom Political Action Committee and the Biocom Institute for education and workforce development. Joe also is a founder and chairman of the California Biotechnology Foundation, a joint initiative to inform legislators and the media about the life science industry in California.
A Vision for Boosting the Life Sciences in San Diego and Beyond
The life sciences industry represents a vital piece of San Diego’s innovation economy, contributing $31.8 billion each year in local economic impact—more than defense or even tourism, according to the San Diego Regional Economic Development Corp. Beyond our region, San Diego’s life sciences community is significant for a different reason: Our companies contribute novel healthcare … Continue reading “A Vision for Boosting the Life Sciences in San Diego and Beyond”
Five Tips for Building a Successful Relationship with the FDA
I recently led an initiative to communicate more proactively and frequently with the leaders of the FDA about issues specifically related to improving the agency’s focus on innovative biomedical and therapeutic technologies. At San Diego’s Biocom, where I am CEO, we believe that both industry and regulators can benefit from an atmosphere of open communication … Continue reading “Five Tips for Building a Successful Relationship with the FDA”